

## Chemocentryx's future in doubt as avacopan foundation crumbles



[Madeleine Armstrong](#)

After Friday's split adcom vote on Chemocentryx's avacopan in ANCA-associated vasculitis, even the sellside seems to have given up on the project's prospects of approval. And a glance at the group's pipeline shows little else to get excited about. Avacopan's chances in hidradenitis suppurativa and C3 glomerulopathy look like a long shot after [mid-stage failures last year](#); Chemocentryx also has plans in lupus, historically a graveyard for biopharma. And any future successes might be tempered by [concerns raised by the FDA about avacopan's liver toxicity](#). So what next for Chemocentryx? The company did not mention its phase 1 asset CCX507 in its latest earnings release, focusing instead on the preclinical oral checkpoint inhibitor CCX559; however, others like [Curis have been working on oral projects for some time now](#) with little progress. Even if Chemocentryx prevails here the PD-(L)1 field is crowded, and bigger players are already developing more convenient options, such as [Pfizer with its subcutaneous asset sasanlimab](#). Chemocentryx's share price plunged 62% on Friday but, with a valuation still well above its \$424m cash balance, there are some hopes that the group can pull a rabbit out of the hat.

### Chemocentryx's pipeline

Project	Description	Indication	Status	2026e sales (\$m)
Avacopan (Vynpenta)	Complement factor C5a inhibitor	ANCA-associated vasculitis	FDA adcom split 9-9 on whether efficacy data support approval; Pdufa July 7	348
		Hidradenitis suppurativa	Failed ph2 Aurora trial but planning ph3 in severe pts	63
		C3 glomerulopathy	Failed ph2 Accolade trial but discussing path forward with FDA	24
		Lupus	Development to start Q4 2021	-
CCX507	CCR9 inhibitor	Ulcerative colitis	Ph1	-
CCX559	Oral PD-L1 inhibitor	Cancer	Preclinical; ph1 to start Q2 2021	-
CCX587	CXCR6 inhibitor	Autoimmune diseases	Preclinical	-

Source: Evaluate Pharma & company presentations.

[More from Evaluate Vantage](#)

Evaluate HQ  
44-(0)20-7377-0800

Evaluate Americas  
+1-617-573-9450

Evaluate APAC  
+81-(0)80-1164-4754

